DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | ABScience | Adocia | AdvicennePharma | Affichem | AgateBioservices | AisaTherapeutics | AlfactInnovation | AlizePharma | Ambiotis | AnacondaPharma | AptysPharmaceuticals | ArianaPharmaceuticals | Aterovax | AtlanticBoneScreen | AureusSciences | BCellDesign | BioAlliancePharma | Biocortech | BioCydex | Biomethodes | Biomup | BioProteinTechnologies | BioQuanta | BioSystemsInternational | BMSystems | Carmat | Cellectis | CellialTechnologies | CellProthera | CellVax | CerenisTherapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBVTechnologies | Diaxonhit | DNATherapeutics | DomainTherapeutics | Dynabio | Edelris | EndotisPharma | Epixis | ERYtechPharma | EyeTechCare | FlamelTechnologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | GenomicVision | GenoSafe | GenoSciencePharma | Genoscreen | GenOway | Genticel | GTPTechnology | HeliosBiosciences | Hemarina | Hybrigenics | HyphenBioMed | Imagene | ImmunId | Immutep | Imstar | InCellArt | IndiciaBiotechnology | IndiciaBiotechnology | InnatePharma | InnaVirVax | InnovativeHealthDiagnostics | IntegraGen | Ipsogen | IStem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | MaunaKeaTechnologies | MedesisPharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | NetrisPharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | ObeTherapy | Oligovax | Oncodesign | OriBasePharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | PherecydesPharma | PolyIntell | Proteogenix | Protexel | PXTherapeutics | QuantumGenomics | RhenoviaPharma | ScarCellTherapeutics | SiseneBiotechnologies | SkuldTech | Stentys | Synapcell | Synprosis | TcLandExpression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | VaxonBiotech | Vectalys | Vivalis | XenTech |


MEMORIES - POUR MÉMOIRE

 

légende

légende

  • Hereafter is a partial list of significant Biotech companies today disappeared or not any more legally French, to witness the memory of those entrepreneurs who took the risks for a risky venture : some were acquired (and a subsidiary may still be active in France), some were merged (and their name absorbed), some were liquidated... but most entrepreneurs started again
  • In a Biotech world that moves swiftly memory soon holds many holes... any data additions-contributions will be highly appreciated using the CONTACTEXPRESS form
  • Beware, obviously, website URL and e-mails may well be outdated
  • Pharmaclient : Mission, Keywords Biotech, Services... MORE?
  • Voici une liste partielle des entreprises Biotechs importantes, aujourd'hui disparues ou bien plus du tout Françaises (légalement), éditée pour rendre hommage aux entrepreneurs qui ont pris des risques pour un projet à risques : certaines ont été acquises (et une filiale peut encore être active en France), certaines ont été fusionnées (et leur nom a été absorbé), certaines ont été liquidées... mais la plupart des entrepreneurs ont recommencé
  • Dans un monde des Biotechs qui bouge très vite, la mémoire tôt se remplit de nombreux trous... toutes additions-contributions pour les données, en utilisant le formulaire de CONTACTEXPRESS seront vivement appréciées
  • Attention, évidemment, les URL et courriels sont probablement obsolètes
  • Pharmaclient : Mission, Mots-clés Biotech, Services... PLUS?

 

ONCE FRENCH BIOTECHS, TODAY ?... HATS-OFF TO VALOROUS TEAMS !

 

ADIATEC, ALPHELYS, APTANOMICS, BIONEXIS PHARMACEUTICALS, BIONISIS, CAREX, CELLPEP, CELLVIR, CELOGOS, CEZANNE, CYTOMICS, DIATOS, DRUGABUSE SCIENCES, ECHOSENS, ENDOCELLS, FOVEA PHARMACEUTICALS, GENODYSSEE, GÉNOPOÏETIC, GENSET, HEMOSYSTEM, IDM PHARMA, IVAGEN, LIBRAGEN, MERISTEM THERAPEUTICS, MICROBIOCHIPS, MITOPROD, MUTABILIS, MYOSIX, NAUTILUS BIOTECH, NEURO3D, NEUROTECH, NOVAGALI, NOVEXEL, OPI, PHARMAXON, PRAXCELL, PROTÉUS, SEPAL PHARMA, SERIAL GENETICS, SHIGAMEDIX, SYNT:EM, THERAPTOSIS, TRANSAT, UROGENE, URRMA, VALIGEN, VIGICELL, ZETA BIOTECH

 

* ADIATEC *


 

1998 - Bretagne
Nantes
www.adiatec.fr

 

Design, Diagnostics
Key words: Immunoassay kits, Ophthalmology, Allergy, Eutest, Lacrytest, Mabtest, Amplitest
Mission: to develop and manufacture rapid assays for in vivo/in vitro diagnostics of ocular allergy, babies and children allergy, and for murine monoclonal antibodies isotyping
Clients: analysis labs, research labs
info@adiatec.fr

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Lesser (Joël) [founder]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev: Brèche (Sébastien)
Financers (Hist.): privately owned, business angels

Turnover (M€) :
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Ophthalmo
Position : Clinical
Company confirm : n.a.

 

History
DATEMILESTONETYPETIME
2005 .12 Company liquidation INFO [7 years]
1998 .01 Company founded by Joël Lesser ORGF [0 year]

Actualisation / Updating: 12-May-2008

 

* ALPHELYS *


 

2001 - IDF
Plaisir
(near Paris)
www.alphelys.com

 

Design, Solutions
Key words: Instruments, Tissue array, Molecular histology, Imaging, Software, Reagents, Tisalys, Cresalys, MiniCore
Mission: to design, develop and market innovative integrated solutions including instruments, software and reagents for pathology and cytogenetics markets
Clients: Pharmaceutical industry, Research labs
info@alphelys.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Chaumat (Pierre) [co-founder, born 1965]
Sc.Dir.-CSO:
SalesMktg: Defrenaix (Pierre) [co-founder]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): none (100% privately owned, capital 2007 = 0.04 M€, 2006 = 0.11 M€)

Turnover (M€) : 2.0 (2007)
Total funding (M€) : 0.4
Last funding (M€) : n.a.
Focus : Multiple
Position : Preclin
Company confirm : none

 

History
DATEMILESTONETYPETIME
2011 .02 Company liquidation INFO [9 years]
2009 .12 Partnering distribution agreement with Biogen (USA) for Brazil market (exclusive distributor) MKTG [8 years]
2008 .05 Partnering distribution agreement with Zytomed Systems (Germany) for immunohistochemical reagents in France MKTG [6 years]
2006 .10 Partnering distribution agreement with Seroa (Monaco) for product portfolio in many countries worldwide MKTG [5 years]
2005 .06 Seed financing : 0.24 M€, by owners, as a capital increase from 0.16 M€ to 0.40 M€ SFIN [3 years]
2002 .02 Company name change from Amelys to Alphelys, due to pre-occupied name INFO [0 year]
2001 .10 Company founded by Pierre Chaumat and Pierre Defrenaix (initially named Amelys) ORGF [0 year]

Actualisation / Updating: 3-May-2011

 

* APTANOMICS *


 

2001 - Rhône-Alpes
Lyon
www.aptanomics.com

 

Discovery, Drugs
Key words: Aptameres, Peptides, Cancer, Aptascreen, Aptaprint
Mission: to develop new treatments based on discovery of targets involved in signalling pathways that are deregulated in a broad range of cancers
Clients: Pharmaceutical industry (own development up to preclinical stage)
info@aptanomics.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Spin-off |
Managing Dir.-CEO: Chatelier (Jean)
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): AGF P.E., CDC Ixis, Ventech, Biogestion

Turnover (M€) : 0.05 (2006)
Total funding (M€) : 7.0
Last funding (M€) : 7.0
Focus : Cancers
Position : Preclin
Company confirm : n.a.

 

History
DATEMILESTONETYPETIME
2007 .07 Financial complete burn-out and bankruptcy INFO [6 years]
2006 .11 Divestiture of some R&D assets to Imaxio (UK) LICOUT [5 years]
2005 .06 Partnering research agreement with Boehringer-Ingelheim in aptamer-based target validation R&D [4 years]
2003 .05 Nomination : Michael Courtney [ex-Transgene], as CEO ORGN [2 years]
2002 .11 1st round-financing : 7 M€, by AGF P.E., CDC Ixis, Ventech RFINA [1 year]
2001 .03 Company founded by John Hawken, Pierre Colas [Inserm, CSO], as a spin-off from Normale Sup (Lyon), based on patents from Massachusetts General Hospital ORGF [0 year]

Actualisation / Updating: 12-May-2008

 

* BIONEXIS PHARMACEUTICALS *


 

2002 - IDF
Paris
www.bionexis.com

 

Discovery, Drugs
Key words: Imaging radio-pharmaceuticals, Targeted drugs, Lipid-protein interaction, Apoptosis, Afim
Mission: to develop intelligent molecules for imaging and therapeutic applications, based on know-how on membrane protein-lipid interactions, focused on pathological apoptosis
Clients: Prescribers
info@bionexis.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Rodgers (Brid) [Ph.D. molecular biology, MBA, ex-Monitor]
Sc.Dir.-CSO: Russo-Marie (Françoise) [co-founder, ex-Inserm] & Samson (Alain) [co-founder, University Professor]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Edmond de Rotschild I.P., Bioam, Sophia Euro lab, FCJE (CDC), CEA

Turnover (M€) :
Total funding (M€) : 6.0
Last funding (M€) : 6.0
Focus : Cancers
Position : Incubator
Company confirm : n.a.

 

History
DATEMILESTONETYPETIME
2004 .12 Company liquidation INFO [2 years]
2004 .02 1st round-financing : 6 M€, led by Edmond de Rotschild I.P., with Bioam, Sophia Euro lab, FCJE (CDC), CEA RFINA [2 years]
2004 .02 Company move from Saclay (CEA) to Paris (Biotech) RELOC [2 years]
2002 .02 Company founded by Françoise Russo-Marie and Alain Samson ORGF [0 year]

Actualisation / Updating: 12-May-2008

 

* BIONISIS *


 

1999 - IDF
Le Plessis (near Paris)
www.bionisis.com

 

Contract, Research
Key words: High-throughput, Purification, OPLC technology (Optimum Performance Laminar Chromatography), Sorbent beds
Mission: to provide third parties with proprietary solutions for the separation, purification and analysis of chemical and biochemical mixtures resulting from organic synthesis, natural product extraction and biological fluids
Clients: Pharmaceutical industry, Research labs
webmaster@bionisis.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Manach (Michel)
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Sofimac, Ventech, Siparex, OTC A.M.

Turnover (M€) : 0.5 (2004)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Multiple
Position : Subcontractor
Company confirm : n.a.

 

History
DATEMILESTONETYPETIME
2008 .03 Company liquidation INFO [8 years]
2002 .09 2nd round-financing : 2.5 M€ RFINB [2 years]
1999 .10 Company founded by unknown entrepreneurs ORGF [0 year]

Actualisation / Updating: 12-May-2008

 

* CAREX *


 

2001 - Alsace
Strasbourg
www.carex.fr

 

Discovery, Drugs
Key words: Diabetes
Mission: to undertake innovative research of metabolic diseases, such as type 2 diabetes, obesity and dyslipidemia
Clients: Pharmaceutical industry
carex@carex.fr

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Race (Geoffrey) [ex-Adprotech]
Sc.Dir.-CSO:
Fin.Dir.-CFO: Margetson (Shelley)
BusDev:
Financers (Hist.): Sofinnova Partners, GIMV, Mara Ventures (USA), Crédit Lyonnais P.E., Global Life Science Ventures, BioMedinvest, HBM

Turnover (M€) :
Total funding (M€) : 31.0
Last funding (M€) : 25.0
Focus : Metabolism
Position : Preclin
Company confirm : n.a.

 

History
DATEMILESTONETYPETIME
2006 .05 Acquisition by 7TM Pharma (Denmark) ACQ- [5 years]
2004 .03 2nd round-financing : 25 M€, by Crédit Lyonnais P.E., Global Life Science Ventures, BioMedinvest, HBM, and previous shareholders RFINB [3 years]
2002 .07 Nomination : Geoffrey Race, as CEO [1 year]
2002 .04 1st round-financing : 6 M€, led by Sofinnova Partners, GIMV and Mara Ventures RFINA [1 year]
2001 .11 Company founded by Johan Auwerx, Pierre Chambon, Samir S. Deeb, Hana Koutnikova, Jürgen M.Lehmann, based on research from Institut de Génétique et de Biologie Moléculaire et Cellulaire, by Pierre Chambon (President of the board) ORGF [0 year]

Actualisation / Updating: 12-May-2008

 

* CELLPEP *


 

1998 - IDF
Paris
www.cellpep.fr

 

Delivery, Drugs
Key words: Generics, Value-added, Long acting release, Formulation, Octreotide, Goserelin
Mission: to develop therapeutics in oncology and infectious diseases
Clients: Pharmaceutical industry
jpboulan@cellpep.fr

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: de Rougé (Bonabes) [co-founder, M.D., ex-Servier, Beaufour-Ipsen]
Sc.Dir.-CSO: Mollard (Michel) [co-founder, also Seventure, ex-Beaufour-Ipsen, Cooper]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Seventure

Turnover (M€) :
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Multiple
Position : Clinical
Company confirm : n.a.

 

History
DATEMILESTONETYPETIME
2006 .03 Acquisition by Procyon (Canada), for 39 MUS$, to form a new legal entity, Ambrilia Biopharma (www.ambrilia.com) ACQ- [8 years]
2003 .03 Round-financing : 3.8 M€, by Turenne Capital Partenaires, OTC Asset Management, H2i Management, Synergènes RFIN [5 years]
1998 .00 Company founded by Bonabes de Rougé, Michel Mollard and others ORGF [0 year]

Actualisation / Updating: 12-May-2008

 

* CELLVIR *


 

2006 - IDF
Évry
(near Paris)
www.cellvir.com

 

Discovery, Drugs
Key words: Anti-retrovirals, AIDS, HCV, SARS, Avian Flu
Mission: to develop a new generation of anti-retrovirals by targeting the host-virus protein-protein interactions
Clients: Pharmaceutical industry (own clinical development up to phase IIa)
michael.courtney@cellvir.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Courtney (Michael) [Scottish, Ph.D., ex-Aptanomics, Noxxon, Trangene (CSO)]
Sc.Dir.-CSO: Benarous (Richard) [co-founder, born 1941, M.D., Ph.D., ex-Hybrigenics (co-founder), Cytomics (co-founder)]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): OSEO, ANRS, ANR, Genopole 1er Jour and INSERM Transfert
Note (February 2010) : the company website is unavailable and the URL does not exist any more (temporarily ?)
Note (October 2010) : the company is announced (unconfirmed) as a 100% subsidiary of Mutabilis, itself a subsidiary of Pharma Omnium International, a private equity fund

Turnover (M€) : n.a.
Total funding (M€) : 2.0
Last funding (M€) : 2.0
Focus : Virus
Position : Incub
Company confirm : neutral

 

History
DATEMILESTONETYPETIME
2010 .11 Company struck off LEGAL [4 years]
2008 .06 Seed financing : 2 M€, by Genopole 1er Jour and Inserm Transfert Initiative SFIN [2 years]
2006 .08 Patent : granted from Inserm (spin-off) LEGAL [0 year]
2006 .03 Company founded by Richard Benarous, Richard Platford, Armand Frydman, E.Thomas Bader, Jean Deregnaucourt ORGF [0 year]

Actualisation / Updating: 5-Apr-2011

 

* CELOGOS *


 

2001 - IDF
Paris
www.celogos.fr

 

Discovery, Drugs
Key words: Muscle regeneration, Cell repair, Technology platform, Rational Cell Design (RCD), Stress urinary incontinence, Anal incontinence, Ocular myopathies
Mission: to develop and produce innovative cell-based technologies in the field of cellular medicine
Clients: Pharmaceutical industry
contact@celogos.fr

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Ulmann (André) [M.D., Ph.D. endocrinology, ex-Hoechst, Roussel Uclaf]
Sc.Dir.-CSO: Pinset (Christian) [founder, M.D., ex-CNRS, Institut Pasteur]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned

Turnover (M€) :
Total funding (M€) : 3.0
Last funding (M€) : n.a.
Focus : Muscle
Position : Preclin
Company confirm : n.a.

 

History
DATEMILESTONETYPETIME
2006 .01 Acquisition by HRA Pharma of majority share, with Celogos maintained as a French subsidiary and Christian Pinset as CSO ACQ- [4 years]
2005 .11 Partnering research agreement, HRA Pharma, for pharmaceutical development process of future lead compounds R&D [4 years]
2001 .08 Company founded by Christian Pinset, cell therapy expert and Didier Montarras (from Institut Pasteur, in Paris) ORGF [0 year]

Actualisation / Updating: 12-May-2008

 

* CEZANNE *


 

2000 - Méditerranée
Nîmes
www.cezanne.fr

 

Development, Devices
Key words: Immunochemistry analysis, Kryptor analyser, Fluorescence detection, Trace technology, Automatic instruments, Reagents
Mission: to develop innovating diagnostics products, notably the the Kryptor system, a software and fluorescence reading system (supplied as an OEM component for Pharma research groups)
Clients: Pharma industry, R&D labs
contact@cezanne.fr

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Bois (Emmanuel) [co-founder, born 1960]
Sc.Dir.-CSO: Bois (Emmanuel)
Fin.Dir.-CFO:
BusDev:
Financers (Hist.):

Turnover (M€) : 15.2 (2009), 17.1 (2008), 12.8 (2006)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Multiple
Position : Trade
Company confirm : none

 

History
DATEMILESTONETYPETIME
2009 .12 Acquisition by Thermo Fisher Scientific (USA) ACQ- [9 years]
2009 .06 Partnering research agreement with Brahms (Germany) and Lumiphore (USA), with incorporation of Lumiphore's complexes into diagnostic tests R&D [9 years]
2003 .09 Partnering sales agreement with Brahms (Germany) as exclusive distributor MKTG [3 years]
2003 .09 Company move to Nîmes, after floods devastated the initial premises in September 2002 ORGL [3 years]
2000 .06 Company founded by Emmanuel Bois and others, in Bagnols-sur-Cèze, to continue the divested diagnostics activities by CisBio International, after their acquisition by Schering AG ORGF [0 year]

Actualisation / Updating: 5-May-2011

 

* CYTOMICS *


 

2000 - IDF
Orsay
(near Paris)
www.cytomics.fr

 

Discovery, Drugs
Key words: Ubiquitin ligases, UbiScreen, High-throughput Screening, Cancer, Nosocomial Fungal Infections
Mission: to discover and develop small molecules controlling protein turnover, to treat serious human diseases, notably inflammatory diseases and cancer and nosocomial fungal infections
Clients: Prescribers
info@cytomics.fr

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Cambou (Bernard) [born 1955, MBA (Essec), ex-StageMark (co-founder), Aventis-Principia, HGS, MIT]
Sc.Dir.-CSO: Hercend (Thierry) [born 1952, oncologist, also Supervisory Board President, Cytomics, BT Pharma]
Fin.Dir.-CFO: Martin (Erwan) [Sup de Co (Toulouse), MBA, ex-Syndex]
BusDev:
Financers (Hist.): Société Générale A.M., Edmond de Rotschild I.P., Truffle Venture

Turnover (M€) : none (2008)
Total funding (M€) : 13.0
Last funding (M€) : 10.0
Focus : Cancers
Position : Preclin
Company confirm : none

 

History
DATEMILESTONETYPETIME
2010 .12 Company liquidation INFO [10 years]
2008 .03 Company move to Orsay (from nearby Gif-sur-Yvette) and rename as Cytomics Pharmaceuticals (from Cytomics Systems) ORGL [7 years]
2007 .10 Financing (no interest loan) : 2.1 M€, by OSEO, to support its ongoing program in the anti-fungal area (second Oseo grant) DEBT [7 years]
2007 .03 Nomination : Bernard Cambou, new CEO, Prof. Dominique Thomas, founder, resigns ORGN [6 years]
2006 .02 2nd round-financing : 10.0 M€, by Edmond de Rotschild I.P., Truffle Venture and previous shareholders RFINB [5 years]
2003 .02 1st round-financing : 3.0 M€, by Société Générale A.M., and others RFINA [2 years]
2000 .04 Company founded by Dominique Thomas, at initially, Gif-sur-Yvette (near Paris), in collaboration with Richard Benarous (initially as Cytomics Systems, then from February 2008, as Cytomics Pharmaceuticals) ORGF [0 year]

Actualisation / Updating: 5-Apr-2011

 

* DIATOS *


 

1999 - IDF
Paris
www.diatos.com

 

Delivery, Drugs
Key words: Drug delivery, Peptides, Tumor targeting, Cancer, Chemotherapy, Prodrugs, Liposome, Vectocell, DaunoXome
Mission: to research, develop and market targeted anti-cancer drugs based on drug-delivery improvements
Clients: Prescribers
contact@diatos.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Spin-off |
Managing Dir.-CEO: Tchelingerian (John) [born 1965, Ph.D. neuroscience, ex-Neurotech (co-founder), Key Obs (co-founder)]
Sc.Dir.-CSO: Gasmi (Jamal) [M.D. Oncology, Ms. Sciences, ex-Roche, Gustave Roussy]
Fin.Dir.-CFO:
SalesMktg: Cowburn (James) [Ph.D. Biochemistry, ex-Zeneus Pharma, Roche, Schering Plough]
BusDev:
Financers (Hist.): GIMV, InterWest Partners, Société Générale A.M., AGF P.E., Sopartec, Sofinnova Partners, NIF, Crédit Lyonnais P.E. (today Crédit Agricole P.E.), Innoven, BFF, Credit Agricole P.E.

Turnover (M€) : 0.49 (2007), 0.30 (2006)
Total funding (M€) : 54.8
Last funding (M€) : 9.4
Focus : Cancers
Position : Trade
Company confirm : none

 

History
DATEMILESTONETYPETIME
2009 .05 Company bankruptcy (in need of € 10 Million re-financing), then liquidation INFO [10 years]
2008 .12 Licensing-out of DTS-108, a pro-drug of irinotecan to Drais (with co-development) LICOUT [9 years]
2008 .08 Clinical trial (phase IIa) for DTS-201, a peptidic prodrug of doxorubicin (beginning) CLIN [9 years]
2007 .07 4th round-financing : 9.4 M€, by Credit Agricole P.E. and previous shareholders RFIND [8 years]
2006 .07 Listing : failure of IPO introduction on Alternext, cancelled due to unfavorable market conditions PBO [7 years]
2006 .05 Licensing-in of specialty cancer product from Gilead LICIN [7 years]
2005 .04 Set-up of US subsidiary in California, USA (Business) ORGC [6 years]
2004 .03 Set-up of subsidiary in Leuven, Belgium (R&D) ORGC [5 years]
2004 .02 3rd round-financing : 7.0 M€, by Innoven and BFF (Biotech Fund Flanders) RFINC [5 years]
2003 .05 2nd round-financing : 9.0 M€, by NIF and Crédit Lyonnais P.E. (today Crédit Agricole P.E.) RFINB [4 years]
2003 .04 Licensing-out of cancer improved-delivery drug development to Medarex LICOUT [4 years]
2000 .10 1st round-financing : 15.5 M€, led by GIMV and InterWest Partners, with Société Générale A.M., AGF P.E., Sopartec, Sofinnova Partners RFINA [1 year]
1999 .05 Seed financing : 1.5 M€, by Sofinnova Partners (subsequently John Tchelingerian joins the company as business developper) SFIN [0 year]
1999 .02 Company founded by Prof. Stratis Avraméas, Dr Thérèse Ternynck, as a spin-off from Institut Pasteur ORGF [0 year]

Actualisation / Updating: 18-May-2009

 

* DRUGABUSE SCIENCES *


 

1997 - Rhône-Alpes
Villeurbanne
(near Lyon)
www.drugabusesciences.com

 

Discovery, Drugs
(also, Delivery, Drugs)
Key words: Antagonism, Addiction, Alcoholism, Toxicomany, Cocaine, Opioids, Naltrexone Depot
Mission: to discover, develop and market medications for the treatment of alcohol and substance abuse and dependence
Clients: Prescribers
mdupire@drugabusesciences.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Langlois (Patrick) [born 1945, ex-Aventis (Board member, Rhône Poulenc]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): CDC Ixis, Canaan Partners, Bionex, Jalla Equities, Palldin Group, 3i, ABN Amro, Ace Management
Note : company initially founded in USA (Hayward, California) in December 1994, with an additional base in Paris in December 1997, then legally moved to France in 2004 (through a reversed merger)

Turnover (M€) : n.a.
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Addiction
Position : Clinical
Company confirm : n.a.

 

History
DATEMILESTONETYPETIME
2008 .05 Company liquidation : legal dissolution INFO [10 years]
2007 .01 Divestiture of assets (product portfolio, including naltrexone) to Elbion (Belgium) for undisclosed terms ACQ- [9 years]
2006 .06 Listing on Alternext processed : 20 M€ expected (failed) PBO [8 years]
2004 .01 Acquisition of mother US company by French subsidiary, with new CEO (Robert Floch) and 4.0 M€ convertible loan by CDC Ixis ACQ+ [6 years]
2001 .04 Round-financing : 27.0 M€, by Canaan Partners, Bionex, Jalla Equities, Palldin Group, 3i, ABN Amro, Ace Management RFIN [3 years]
1999 .10 Round-financing : 21.0 M€, by 3i, ABN Amro, Auriga, CDC Innovation, Financière de Brienne, Nomura, Parnib, Partech, Rothschild Asset Management, Société Générale A.M. RFIN [1 year]
1997 .12 Company founded by Philippe Pouletty (today Truffle Ventures), with name also shortened as DAS ORGF [0 year]

Actualisation / Updating: 12-May-2008

 

* ECHOSENS *


 

2001 - IDF
Paris
www.echosens.com

 

Discovery, Devices
Key words: Obesity, Hepatitis C, Hepatitis B, Fibroscan
Mission: to develop, manufacture and market new diagnostic devices in the field of hepatology (FibroScan being the first and only non-invasive device for diagnosis and monitoring of hepatic fibrosis)
Clients: Hospitals (through distributors and subsidiaries)
communication@echosens.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Guillaume (Richard) [born 1955, ex-Blatchford, Abbott, Mead Johnson]
Sc.Dir.-CSO: Sandrin (Laurent) [co-founder, ESCPI, Ph.D. physics, ex-LOA]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): OTC Asset Management, Cap Décisif

Turnover (M€) : 8.1 (2008), 7.2 (2007)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Liver
Position : Clinical
Company confirm : neutral

 

History
DATEMILESTONETYPETIME
2011 .03 Acquisition by Inner Mongolia Free Han & Mongolia Pharmaceuticals (China), for undisclosed sum ACQ- [9 years]
2008 .12 Nomination : Richard Guillaume, new CEO, replacing Bertrand Fourquet ORGN [7 years]
2007 .00 Set-up of 3 subsidiaries in Spain, Germany and China, more than 330 FibroScan® installed worldwide ORGC [5 years]
2004 .00 Round-financing : undisclosed M€, by OTC and Cap Décisif, beginning of the commercialization of FibroScan with dedicated probe in France RFIN [2 years]
2003 .11 CE mark obtained for FibroScan MKTG [2 years]
2001 .06 Company founded by Sylvain Yon [born 1974], Bertrand Fourquet [Essec, as CEO], Laurent Sandrin, Jean-Michel Hasquenoph [ESTP], supported by ANVAR ORGF [0 year]

Actualisation / Updating: 4-Apr-2011

 

* ENDOCELLS *


 

2004 - IDF
Paris
www.no-website.net

 

Design, Therapy
Key words: Cell therapy, Transplantation, Type 1 Diabetis, Insulin
Mission: to generating lines of human pancreatic beta cells immortalized in culture for transplantation therapies
Clients: Research labs
dslagel@esperanteventures.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Slagel (Dean) [born 1970]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.):

Turnover (M€) :
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Diabetes
Position : Incub
Company confirm : n.a.

 

History
DATEMILESTONETYPETIME
2008 .05 Acquisition by Esperante Ventures (Holland) ACQ- [3 years]
2004 .08 Company founded by Prof. Paul Czernichow [M.D. pediatry], Raphaël Scharfmann [Inserm] ORGF [0 year]

Actualisation / Updating: 24-Sep-2008

 

* FOVEA PHARMACEUTICALS *


 

2005 - IDF
Paris
www.fovea-pharma.com

 

Discovery, Drugs
Key words: Ophthalmology, Allergy conjunctivitis, Mavular edema, Retinitis pigmentosa
Mission: to discover and develop new treatments focused on ocular diseases (dry eye, age-related macular degeneration, retinitis pigmentosa, diabetic retinopathy), with a special focus on retinal pathologies
Clients: Pharmaceutical industry (own development, up to preclinical)
info@fovea-pharma.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Gilly (Bernard) [born 1957, Ph.D. bioeconomy, ex-Sofinnova, Transgene (CEO), Pasteur-Mérieux-Connaught]
Sc.Dir.-CSO:
Fin.Dir.-CFO: Davitian (Bernard) [born 1960, MBA, ex-Neurotech (CEO), Transgene, Pasteur-Mérieux]
Oper.Dir.: Bélichard (Pierre) [ex-Urogene, Ethypharm, Fournier]
BusDev: Sternberg (Garry) [M.D., MBA, ex-Eyetech, BMS]
Financers (Hist.): Sofinnova Partners, CAPE, Abingsworth Mangement, The Wellcome Trust, GIMV

Turnover (M€) : 0.04 (2007), 0.005 (2006)
Total funding (M€) : 50.5
Last funding (M€) : 30.0
Focus : Ophthalmo
Position : Preclin
Company confirm : neutral

 

History
DATEMILESTONETYPETIME
2009 .10 Acquisition by Sanofi Aventis (France), for 370 M€ (maximum, depending on milestones) ACQ- [4 years]
2009 .05 Clinical trial (proof-of-concept, positive) for Prednisporin (FOV1101) in patients with persistent allergic conjunctivitis CLIN [4 years]
2009 .02 Licensing-in of European rights of an ocular formulation of DX-88 for the treatment of retinal diseases from Dyax LICIN [3 years]
2007 .12 2nd round-financing : 30.0 M€, by previous shareholders RFINB [2 years]
2007 .11 Partnering research agreement with Genzyme R&D [2 years]
2005 .11 1st round-financing : 20.5 M€, by Sofinnova Partners, CAPE, Abingsworth Management, The Wellcome Trust, GIMV RFINA [0 year]
2005 .05 Company founded by Bernard Gilly, Pierre Bélichard, Prof. José-Alain Sahel (professor, Ophthalmology), based on platform from INSERM research unit 592 ORGF [0 year]

Actualisation / Updating: 5-Oct-2009

 

* GENODYSSEE *


 

1999 - IDF
Évry
(near Paris)
www.genodyssee.com

 

Discovery, Drugs
Key words: Protein optimization, Low-burn model, Interferon, HCV
Mission: to discover superior protein products by using a unique, IP-protected approach and a proprietary genomic DNA databank
Clients: Prescribers
escary@genodyssee.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Escary (Jean-Louis) [founder, born 1964, Ph.D. molecular biology, ex-UCLA, CNG, ]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Matignon I.F., Edmond de Rotschild Fin., Société Générale A.M., George Cohen

Turnover (M€) : 0.11 (2007), 0.17 (2006)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Virus
Position : Preclin
Company confirm : none

 

History
DATEMILESTONETYPETIME
2010 .10 Company liquidation INFO [11 years]
2008 .02 Patent : notice of Allowance of US Application for lead compound (Interferon alpha variant 17) LEGAL [8 years]
2006 .10 Partnering research agreement with Baxter on therapeutic proteines derived from natural genetiques variations R&D [7 years]
2000 .05 1st round-financing : 8.1 M€, led by Matignon I.F., with Edmond de Rotschild Fin., Société Générale A.M., George Cohen RFINA [0 year]
1999 .10 Company founded by Jean-Louis Escary (the first company incubated at Evry Genopole) ORGF [0 year]

Actualisation / Updating: 5-Apr-2011

 

* GÉNOPOÏETIC *


 

1993 - Rhône-Alpes
Miribel (Ain)
www.genopoietic.fr

 

Discovery, Drugs
Key words: Autologous vaccine
Mission: to develop autologous chondrocytes for cartilage repair, gene therapy to treat cancer, as well as to treat graft-versus-host disease (innovative anticancer drugs)
Clients: Pharmaceutical industry
info@genopoietic.fr

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Star-up |
Managing Dir.-CEO: Fourthin (Isabelle) [M.D., MBA Essec, ex-MSD, Osteotech]
Sc.Dir.-CSO: Fourthin (Isabelle)
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Rhône-Poulenc Rorer (Gencells), then Avax (listed on US Stock Exchange)

Turnover (M€) : n.a.
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Cancers
Position : Clinical
Company confirm : n.a.

 

History
DATEMILESTONETYPETIME
2008 .11 Nomination : François R. Martelet (Avax CEO since 2007) as President, and Isabelle Fourthin as Managing Director ORGN [14 years]
2000 .08 Acquisition by Avax Technologies, Philadelphia (USA) ACQ- [6 years]
1994 .11 Round-financing : undisclosed M€, by Rhône-Poulenc Rorer (France), against a minority share to support gene therapy trials RFIN [0 year]
1993 .12 Company founded by David Klatzmann and Jean-Loup Salzmann with the support of UPMC (Université Pierre et Marie Curie), with Charles Salzmann as CEO ORGF [0 year]

Actualisation / Updating: 12-May-2008

 

* GENSET *


 

1989 - IDF
Paris
www.genset.fr

 

Discovery, Drugs
Key words: Pharmacogenomics, DNA sequences
Mission: to undertake research programs in the field of genomics, to analyze the regulatory sequences of the human genome and to initiate the construction of a map of single nucleotide polymorphisms as a tool to accelerate the discovery of genes associated with diseases, notably for CNS and metabolism
Clients: Pharmaceutical industry, Research labs
contacts@genset.fr

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Pernet (André)
Sc.Dir.-CSO: Vassuer (Marc) [co-founder, Ph.D.]
Pharm.Dir.: Ravel (Denis) [Ph.D.]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): J.P. Morgan, Public
Note : in 1999, Genset reported identifiable assets of 80.9 Million € and had subsidiaries in USA, Japan, Singapore, and Australia

Turnover (M€) :
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Multiple
Position : Incub
Company confirm : n.a.

 

History
DATEMILESTONETYPETIME
2002 .06 Acquisition by Serono (Switzerland) [today Merck-Serono] ACQ- [13 years]
1996 .06 Listing on Nasdaq : 100 MUS$ (about 80 M€) PBO [7 years]
1989 .00 Company founded by Marc Vasseur (a leading French scientist), Pascal Brandys (CEO, venture capitalist) ORGF [0 year]

Actualisation / Updating: 12-May-2008

 

* HEMOSYSTEM *


 

1999 - Méditerranée
Marseille
www.hemosystem.com

 

Discovery, Diagnostics
Key words: Bacteria, Micro-array, ScanSystem
Mission: to develop new diagnostic tools and associated devices to improve safety in blodd transfusion medecine
Clients: Blood transfusion centers, Hospitals
info@hemosystem.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Hermet (Jean-Pierre) [founder, MBA, ex-Bentley Pharma, American Home Products, Allergan]
Sc.Dir.-CSO: Besson-Faure (Isabelle) [Pharm.D., ex-Stago]
Fin.Dir.-CFO: Allione (Monique) [Sup de Co (Marseille), DESCF, ex-Quater Oats, Irex (Synthelabo)]
BusDev:
Financers (Hist.): Société Générale A. M., XAnge, Avenir Finance Gestion, FJCE (CDC)

Turnover (M€) : 0.7 (2004)
Total funding (M€) : 5.3
Last funding (M€) : 3.0
Focus : Hematology
Position : Trade
Company confirm : n.a.

 

History
DATEMILESTONETYPETIME
2006 .10 Company liquidation INFO [7 years]
2004 .09 Round-financing : 3.0 M€, by FCJE (CDC), and previous shareholders RFIN [5 years]
1999 .05 Company founded by Jean-Pierre Hermet (CEO) ORGF [0 year]

Actualisation / Updating: 12-May-2008

 

* IDM PHARMA *


 

1987 - IDF
Paris
www.idm-biotech.com

 

Discovery, Drugs
Key words: Melanoma, Sarcoma, Infectious diseases, Junovan
Mission: to develop innovative products that activate the immune system to treat cancers
Clients: Prescribers
idm@idm-biotech.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Romet-Lemonne (Jean-Loup) [co-founder]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.):

Turnover (M€) :
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Cancers
Position : Clinical
Company confirm : n.a.

 

History
DATEMILESTONETYPETIME
2009 .05 Acquisition by Takeda, for US$ 75 Million ACQ- [22 years]
2008 .02 Partnering research agreement ended with Sanofi-Aventis, after disappointing results on Junovan R&D [21 years]
2007 .06 Nomination : Timothy Walbert, new CEO and Chairman, with resignation by founder Jean-Loup Romet-Lemonne ORGN [20 years]
2005 .03 Acquisition by Epimune, as a merger with name change from IDM to IDM-Pharma ACQ- [18 years]
2002 .12 Round-financing : 20.0 M€, by Sanofi-Synthelabo (exclusive, shareholding : 11%) RFIN [15 years]
2002 .01 Partnering research agreement with Sanofi-Synthelabo R&D [15 years]
2000 .11 Round-financing: 48.9 M€ RFIN [13 years]
1993 .12 Company founded by Jean-Loup Romet-Lemonne (as Immuno-Designed Molecules, IDM) ORGF [6 years]

Actualisation / Updating: 5-Jun-2009

 

* IVAGEN *


 

2002 - Méditerranée
Bernis
(near Nîmes)
www.ivagen.com

 

Discovery, Diagnostics
Key words: Immuno-hematology, Medical devices, HIV, H5N1
Mission: to develop, manufacture and distribute reagents to assist third parties in human, veterinary and plant diagnosis, and to discover proprietary immuno-diagnostics
Clients: Research labs
contact@ivagen.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Skorski (Gilbert) [born 1955]
Sc.Dir.-CSO: Da Costa (Jean-Manuel)
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Matignon I.G., OTC Asset Management (33%)
Communication: website under construction, since long

Turnover (M€) : 1.05 (2006)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Virus
Position : Trade
Company confirm : none

 

History
DATEMILESTONETYPETIME
2008 .07 Company liquidation INFO [6 years]
2007 .04 Round-financing : undisclosed M€, by Matignon I.G., OTC Asset Management (after receivership in 2004) RFIN [5 years]
2002 .02 Company founded by Jean-Claude Aziza (unexpectedly deceased in 2006), Gilbert Skorski ORGF [0 year]

Actualisation / Updating: 31-Oct-2008

 

* LIBRAGEN *


 

2001 - Midi-Pyrénées
Toulouse
www.libragen.com

 

Design, Manufacturing
(also, Contract, Research)
Key words: Bioprocesses, Enzymes, Bio-catalysis, Meta-Dna libraries, Small molecules identification, Micro-organisms, Auriose
Mission: to discover, develop and improve innovative bioprocesses for the industrial production of healthcare molecules, by building on bacterial diversity, based on cooperation with 4 Public research units (Inra, Insa, Lyon CNRS, Orsay CNRS)
Clients: Pharmaceutical industry, Chemical industry, Cosmetics industry, Food industry
contact@libragen.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Nalin (Renaud) [born 1967, Ph.D., ex-CRO]
Sc.Dir.-CSO: Lefèvre (Fabrice) [Ph.D., Insa, ex-Protéus]
Tech-Dev: Auriol (Daniel) [Ph.D. biochemical engineering, ex-CRITT, Solabia]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Bioam, Galia Gestion, CDC Entreprises, Irdi, Socri

Turnover (M€) : 0.69 (2009), 0.31 (2008), 0.18 (2007)
Total funding (M€) : 3.0
Last funding (M€) : 2.2
Focus : Studies
Position : Proof-of-Concept
Company confirm : none

 

History
DATEMILESTONETYPETIME
2010 .12 Acquisition by Induchem (Switzerland) ACQ- [9 years]
2010 .04 Launch of NovHyal, a new cosmetic formulation in S3D regenerative serum MKTG [9 years]
2010 .01 Sustainable process intensification in the manufacturing of its cosmetic actives, Inoveol MKTG [8 years]
2008 .12 Launch of Inoveol (www.inoveol.com) actives (stable polyphenol cosmetic compounds) on the US market MKTG [7 years]
2008 .09 Partnering research agreement with DSM, to co-develop transaminases for production of chiral amines R&D [7 years]
2006 .01 Partnering research agreement with Pierre Fabre, enzymatic synthesis R&D [4 years]
2005 .11 Partnering research agreement with Minakem on biocatalysis and organic synthesis (green chemistry, fine chemicals) R&D [4 years]
2005 .06 Nomination : Fabrice Lefèvre, as CSO ORGN [4 years]
2004 .09 Company move from Lyon to Toulouse ORGL [3 years]
2004 .05 1st round-financing : 2.2 M€, by BIOAM, Galia Gestion, and IRDI (Midi Pyrénées V.C.) RFINA [3 years]
2001 .03 Seed financing : 0.75 M€, by Bioam SFIN [0 year]
2001 .02 Company founded by Renaud Nalin and Pascal Simonet [CNRS] in Lyon ORGF [0 year]

Actualisation / Updating: 9-May-2011

 

* MICROBIOCHIPS *


 

2006 - IDF
Paris
www.microbiochips.com

 

Design, Diagnostics
Key words: Biochip, Micro-arrays, Cytokine, Anti-body, MicroVigene
Mission: to speed up third parties research with customized designed micro-arrays and to exclusively distribute in Europe micro-arrays from other biotech companies (also to develop own micro-arrays, as nano-arrays, in partnership with Toulouse CNRS)
Clients: Pharmaceutical industry, Agro industry, Cosmetics industry
after-sales-services@microbiochips.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Saulot (Vincent) [co-founder, born 1975, Ph.D., Eng. Insa, ex-BioMedical Diagnostic, Chiron]
Sc.Dir.-CSO: Malingue (Frédéric) [ex-Biorad]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€)

Turnover (M€) : 0.21 (209), 0.25 (2008), 0.23 (2007), none (2006)
Total funding (M€) : 0.3
Last funding (M€) : 0.3
Focus : Multiple
Position : Trade
Company confirm : none

 

History
DATEMILESTONETYPETIME
2010 .09 Acquisition by BioSystems International (by partial transfer of assets of MBC to BSI) with company struck off on August 17. 2011 ACQ- [4 years]
2010 .02 Licensing-in of PlasmaScan antibody microarray products that speed-up identification of human plasma biomarkers from Biosystems LICIN [3 years]
2009 .01 Partnering marketing agreement (worldwide) with Abcam on custom antibody arrays MKTG [2 years]
2008 .08 Company move from Evreux to Paris with 10 times more space ORGL [2 years]
2008 .07 Set-up of UK subsidiary in London (led by Pascal Azabian) ORGC [2 years]
2008 .06 Certification : ISO 9001-2000 INFO [2 years]
2007 .02 Partnering distribution agreement with Vigene Tech, for the US market MKTG [0 year]
2006 .05 Company founded by Dr Vincent Saulot and Pascal Azabian, based in Evreux incubator ORGF [0 year]

Actualisation / Updating: 28-Sep-2011

 

* MERISTEM THERAPEUTICS *


 

1998 - Centre
Clermont-Ferrand
www.meristem-therapeutics.com

 

Design, Drugs
(also Discovery, Drugs)
Key words: Therapeutic Proteins, Gene technology, Plants, MABs, Manufacturing, Processing, Third Parties, Merispase, Cystic fibrosis
Mission: to produce therapeutic proteins (e.g., monoclonal antibodies) for third parties needs, with many advantages in comparison to other systems (biological safety, high flexibility, low cost), and to develop own portfolio of innovative therapeutic proteins
Clients: Pharmaceutical industry, Biotechs
meristem@meristem-therapeutics.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Rohmer (Jean-Paul) [born 1947, Ph.D. Management, Dauphine, ex-Eli Lilly, Stallergènes (CEO)]
Sc.Dir.-CSO: Burtin (Daniel) [Ph.D. Biochemistry, ex-INRA]
Oper.Dir.: Boisgard (Catherine) [ex-Human Resources]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Limagrain (Unigrains), BNP, Tethys, 3i, Sofipar, Sofimac, AGF P.E., Antin Innovation, CPR P.E., Innoven, Edmond de Rotschild I.P., Odyssée Ventures, Pechel Industrie, SPEF

Turnover (M€) : 0.17 (2006)
Total funding (M€) : 60.0
Last funding (M€) : n.a.
Focus : Multiple
Position : Trade
Company confirm : none

 

History
DATEMILESTONETYPETIME
2008 .08 Company liquidation INFO [10 years]
2007 .10 Court : applications on appeal for GMO corn testing, rejected by tribunal LEGAL [9 years]
2004 .02 Nomination : Jean-Paul Rohmer, chairman of Supervisory Board ORGN [5 years]
2002 .06 4th round-financing : 21.5 M€, by AGF P.E., Antin Innovation, CPR P.E., Innoven, Edmond de Rotschild I.P., Odyssée Ventures, Pechel Industrie, SPEF, and previous shareholders RFIND [4 years]
2001 .07 Listing : failure of IPO introduction due to unfavorable financial environment for 54 M€ expected PBO [3 years]
2000 .11 Acquisition of Sedaherb, phyto-subcontractor to pharmaceutical industry, for around 1 year turnover, 3.5 M€ ACQ+ [2 years]
2000 .06 3rd round-financing : 10.0 M€, by BNP, Tethys, 3i, Sofipar, Sofimac RFINC [2 years]
1999 .02 2nd round-financing : 18.3 M€, by Banexi Ventures 2, Banexi, 3i, Sofimac (Société de Financement du Massif Central), Sofipar (groupe Crédit Agricole) and capital disposal by Limagrain to the financial investors RFINB [0 year]
1998 .05 1st round-financing : 10.0 M€, by Limagrain RFINA [0 year]
1998 .04 Company founded by Limagrain (Agro-food cooperative company, the number one seed producer in Europe), based on an innovative technology (Molecular Pharming) developped since 1992 ORGF [0 year]

Actualisation / Updating: 16-Feb-2009

 

* MITOPROD *


 

2004 - Aquitaine
Bordeaux
www.mitoprod.com

 

Contract, Manufacturing
Key words: RNA-factory, Mitochondrial DNA, Yeast, Custom nucleotides, RNA Genix
Mission: to use proprietary technology of RNA production based on its own exclusive license in order to produce most promising molecules for third parties
Clients: Pharmaceutical industry
contact@mitoprod.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Plane (Guillaume) [born 1978, co-founder, Ms. biochemistry (Bordeaux)]
Sc.Dir.-CSO:
Fin.Dir.-CFO: Perrin (Patrick) [Ms. economy, ex-Flamel Technology, Ernst&Young]
Techn.Dir.-CTO: Schaal (Oriane) [Ph.D., ex-Covalab]
BusDev: Amandine (Jacques)
Financers (Hist.): Aquitaine Création Innovation, Business angels, privately owned

Turnover (M€) : 0.059 (2007)
Total funding (M€) : 2.2
Last funding (M€) : 1.6
Focus : Multiple
Position : Trade
Company confirm : none

 

History
DATEMILESTONETYPETIME
2011 .03 Company liquidation INFO [6 years]
2009 .03 Partnering distribution agreement with Sigma-Aldrich for Customized Long RNA Oligonucleotides MKTG [4 years]
2009 .01 Patent : granted on new class of interfering RNA, called ciRNA (circularization of the active molecules) LEGAL [4 years]
2008 .02 Partnering distribution agreement with Eurobio Labs for European market MKTG [3 years]
2006 .05 1st round-financing : 1.6 M€, by undisclosed investors RFINA [1 year]
2005 .05 Seed financing : 0.14 M€, by Aquitaine Création Innovation SFIN [0 year]
2004 .09 Company founded by Guillaume Plane (CEO), Nathalie Bonnefoy [CNRS], based on a technology discovered by Dr. Jean-Paul di Rago [CNRS, also co-founder] ORGF [0 year]

Actualisation / Updating: 3-May-2011

 

* MUTABILIS *


 

2001 - IDF
Romainville
(near Paris)
www.mutabilis.fr

 

Discovery, Drugs
Key words: Antibacterials, Severe infections, Nosocomial diseases
Mission: to identify and develop new antibacterial therapies in the fields of vaccines, antibodies and classic antibiotics
Clients: Prescribers
partners@mutabilis.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Spin-off |
Managing Dir.-CEO: Stéphane Huguet [born 1955, President P.O.I., ex-Pharmacia, Phoenix, Fournier, Sandoz]
Sc.Dir.-CSO: Escaich (Sonia) [Ph.D., ex-Sandoz, Rhône Poulenc]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Bioam, AXA P.E., Inserm-Transfert, Auriga Partners, Crédit Lyonnais P.E. (today Crédit Agricole P.E.)
Note : website revamped in May 2008, URL changed from «.com» to «.fr» in December 2009 with a single page and mention of company owned by Pharma Omnium International (a private equity fund) which also announces to own CellVir in October 2010, URL vanished in 2011

Turnover (M€) : 0.13 (2008), 0.12 (2006)
Total funding (M€) : 10.2
Last funding (M€) : 8.0
Focus : Infections
Position : Clinical
Company confirm : none

 

History
DATEMILESTONETYPETIME
2010 .06 Company struck off LEGAL [8 years]
2009 .06 Acquisition by start-up Pharma Omnium International (France), with company name maintained and Stéphane Huguet (Président POI), back as CEO ACQ- [7 years]
2007 .10 Nomination : Stephan Fischer as CEO ORGN [6 years]
2005 .04 Partnering research agreement with Chiron (today Novartis) to develop new generation of prophylactic vaccines R&D [3 years]
2004 .06 2nd round-financing : 8.0 M€, by Auriga Partners, Crédit Lyonnais P.E. (today Crédit Agricole P.E.), and previous shareholders RFINB [2 years]
2002 .07 1st round-financing : 2.0 M€, by Bioam, AXA P.E., Inserm-Transfert RFINA [0 year]
2002 .03 Nomination : Stéphane Huguet [ex-Pharmacia, Phoenix, Fournier, Sandoz] as CEO ORGN [0 year]
2001 .08 Company founded by Prof. Xavier Nassif, as a spin-off from Inserm ORGF [0 year]

Actualisation / Updating: 5-Apr-2011

 

* MYOSIX *


 

2000 - IDF
Paris
www.myosix.com

 

Discovery, Immunology
Key words: Cell Transplantation, Muscle cells, Myopathies, Saint-Louis, Genzyme
Mission: to develop cell-based therapies for diseases with unmet medical needs, such as myopathies, based on expertise in muscle cell technology
Clients: Hospitals
contact@myosix.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Academic |
Managing Dir.-CEO: Deleuze (Christian) [Genzyme, Med.Dr, ESSEC 1994, ex-Daiichi-Sankyo, Pharmacia, Searle, Bayer, Pasteur-Mérieux-Connaught]
Sc.Dir.-CSO: Dalle (Bruno) [Pharm.D.]
Fin.Dir.-CFO:
BusDev: Ritsou (Elena)
Financers (Hist.): privately owned (51%), Genzyme (49%)

Turnover (M€) : 0.05 (2008), 0.06 (2007), 0.03 (2006)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Muscle
Position : Clinical
Company confirm : none

 

History
DATEMILESTONETYPETIME
2011 .02 Company liquidation INFO [10 years]
2010 .09 Nomination : Christian Deleuze as CEO ORGN [10 years]
2010 .02 Patent : granted in EU, for MX' technology, on new class of interfering RNA, called ciRNA (circularization of the active molecules) LEGAL [9 years]
2008 .09 Certification : cell therapy laboratory as an authorized center to prepare Cell Therapy Product of clinical use, by AFSSAPS INFO [8 years]
2008 .04 Partnering manufacturing agreement with Association Française contre les Myopathies (AFM, i.e. French Muscular Dystrophy Association) to support research on muscular pathologies and cell therapy INDUS [7 years]
2007 .04 Production : cell therapy (beginning) in Saint Louis hospital (Paris) INDUS [6 years]
2002 .11 Clinical trial (phase II) for cell therapy (beginning, first worldwide) CLIN [2 years]
2002 .07 Partnering research agreement with Genzyme, including capital sharing (49%) R&D [1 year]
2000 .09 Company founded by Dr Jean-Thomas Vilquin, Prof. Jean-Pierre Marolleau and Dr Scorsin, from a patent application on myoblast production technology filed by AP-HP, AFM (French Muscular Dystrophy Association) and INSERM ORGF [0 year]

Actualisation / Updating: 9-May-2011

 

* NAUTILUS BIOTECH *


 

2000 - IDF
Évry
(near Paris)
www.nautilusbiotech.com

 

Delivery, Drugs
Key words: Therapeutic Proteins, Slow-released HGH, Interferon alpha, Vitatropin, Belerofon
Mission: to develop therapeutic proteins with novel and superior pharmacological profiles compared with established best-in-class protein drugs
Clients: Prescribers
contact@nautilusbiotech.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Parkinson (Philip) [born 1956, MBA, ex-Pfizer France]
Sc.Dir.-CSO: Drittanti (Lila) [ex-Genethon]
Fin.Dir.-CFO:
BusDev: Vega (Manuel) [co-founder, born 1960, Ph.D., ex-Microgen, Genethon]
Financers (Hist.): Auriga Partners, Matignon Tech, Edmond de Rothschild I.P., FCJE (CDC), 123 Ventures, Creabilis Therap.

Turnover (M€) : 0.38 (2006)
Total funding (M€) : 25.3
Last funding (M€) : 8.4
Focus : Multiple
Position : Prereg
Company confirm : none

 

History
DATEMILESTONETYPETIME
2008 .11 Company liquidation INFO [8 years]
2007 .04 Clinical trial (phase I) for Belerofon in USA (beginning) CLIN [7 years]
2007 .04 4th round-financing : 8.4 M€, by Pre-IPO Invest, Auriga Partners, Matignon Tech, Edmond de Rothschild I.P., FCJE (CDC), 123 Ventures, Creabilis Therap. RFIND [7 years]
2007 .02 Partnering research agreement with Wyeth on hemophilia therapies R&D [7 years]
2005 .02 3rd round-financing : 7.25 M€, by Auriga Partners, Matignon Tech, Edmond de Rothschild I.P., FCJE (CDC), 123 Ventures, Creabilis Therap. RFINC [5 years]
2005 .02 Nomination : Philip Parkinson as CFO (then CEO, in 2007) ORGN [5 years]
2003 .10 Nomination : Reinhard Koenig [M.D.], as Vice President Clinical & Regulatory Affairs of Nautilus Biotech USA ORGN [3 years]
2000 .08 1st round-financing : 0.9 M€, by undisclosed investors RFINA [0 year]
2000 .01 Company founded by Dr Manuel Vega (CEO) et Paul Martin ORGF [0 year]

Actualisation / Updating: 11-Jan-2009

 

* NEURO3D *


 

2000 - Alsace
Mulhouse
www.neuro3d.com

 

Discovery, Drugs
(also, Contract, Research)
Key words: CNS, Psychiatry, Schizophrenia, Ocaperidone
Mission: to develop innovative treatments for psychiatric disorders such as schizophrenia, depression or anxiety
Clients: Prescribers
contact@neuro3d.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Woler (Charles)
Sc.Dir.-CSO:
Fin.Dir.-CFO: Coste (Julien)
BusDev:
Financers (Hist.): Sofinnova Partners, Apax Partners

Turnover (M€) : 1.0 (2004)
Total funding (M€) : 70.0
Last funding (M€) : 31.5
Focus : Multiple
Position : Clinical
Company confirm : n.a.

 

History
DATEMILESTONETYPETIME
2007 .03 Liquidation and divestiture of R&D assets to Evotec (Germany) INFO [6 years]
2005 .05 Clinical trial (phase III) for key lead compound, ocaperidone, licensed to J&J (beginning) CLIN [4 years]
2004 .12 4th round-financing : 31.5 M€, by previous shareholders RFIND [4 years]
2003 .09 3rd round-financing : 10.0 M€, by previous shareholders RFINC [3 years]
2003 .05 Acquisition of Neurofit (France), a biotech CRO ACQ+ [2 years]
2002 .09 2nd round-financing : 20.0 M€, led by HealthCap, with Techno Venture Management and previous shareholders RFINB [2 years]
2002 .03 Licensing-out of Ocaperidone to Janssen (J&J) LICOUT [1 year]
2000 .11 1st round-financing : 7.6 M€, by founder V.C., Apax Partners RFINA [0 year]
2000 .09 Company founded by Sofinnova, Charles Woler (CEO), Jean-Jacques Bourguignon, Jean-Paul Macher ORGF [0 year]

Actualisation / Updating: 12-May-2008

 

* NEUROTECH *


 

1998 -
www.neurotech.fr

 

Discovery, Drugs
Key words: Retinatis, CNTF, Encapsulated Cell Technology
Mission: to develop sight-saving therapeutics for chronic retinal diseases
Clients: Prescribers
t.shepherd@neurotech.fr

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Shepherd (Tom)
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.):

Turnover (M€) :
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Ophthalmo
Position : Clinical
Company confirm : n.a.

 

History
DATEMILESTONETYPETIME
2006 .06 Company move from Paris to Delaware (USA), as the legal domicile, with change in nationality and website as www.neurotechusa.com ORGL [8 years]
2003 .11 4th round-financing : 12.0 M€, led by Apax Partners and Merlin Biosciences, with previous shareholders (3i Plc, GIMV, West LB, Atlas Venture and Ergo Equity) RFIND [5 years]
2002 .01 Licensing-in agreement of CNTF with Amgen in all ophthalmology indications LICIN [4 years]
2001 .05 3rd round-financing : 35.0 M€, led by Apax Partners and Merlin Biosciences with Westdeutsche Landesbank Girozentrale, ABN Amro, Rotschild, AGF Innovation, and previous shareholders (3I Plc, GIMV, Atlas Venture, CDC Innovation, Sofinnova, Sudinnova, Banque de Vizille, IMH) RFINC [3 years]
2000 .00 Set-up of US subsidiary in Lincoln ORGC [1 year]
1998 .10 Company founded by unknown entrepreneurs ORGF [0 year]

Actualisation / Updating: 12-May-2008

 

* NOVAGALI *


 

2000 - IDF
Évry
(near Paris)
www.novagali.com

 

Delivery, Drugs
Key words: Ophthalmology, Conjunctivitis, Dry eye, Glaucoma, Retinopathies, Novasorb, Eyeject, Cationorm
Mission: to develop a broad portfolio of innovative ophthalmic products addressing the numerous needs of patients suffering from ocular conditions
Clients: Pharmaceutical industry (own development up to registration)
novagali@novagali.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Martinez (Jérôme) [born 1960, Pharm.D., Pharmaco-economics, HEC, MBA, ex-Ethypharm, Lavipharm, Roussel Uclaf, Alliance Santé]
Sc.Dir.-CSO: Buggage (Ronald) [M.D., ex-Pfizer, Novartis]
Fin.Dir.-CFO: Parkinson (Philip) [MBA, ex-Nautilus Biotech, Pfizer]
R&D: Garrigue (Jean-Sébastien) [Pharm.D., MBA, ex-Batelle]
Financers (Hist.): CDC Enterprise Innovation, Auriga Ventures, 123 Multinova, FJCE (CDC), Crédit Agricole P.E., Edmond de Rothschild I.P., Siparex, Bernard Chauvin (B.A.)

Turnover (M€) : 0.98 (2011), 0.59 (2010), 0.43 (2009), 0.41 (2008), 0.02 (2006)
Total funding (M€) : 81.0
Last funding (M€) : 22.0
Focus : Ophthalmo
Position : Launch
Company confirm : neutral

 

History
DATEMILESTONETYPETIME
2011 .09 Acquisition by Santen (preliminary approval to acquire 100% stake for 102 M€, finalized in December) ACQ- [11 years]
2011 .08 Clinical trial (phase III) for Catioprost (completion, positive) CLIN [11 years]
2011 .04 Clinical trial (phase III) for Cyclokat, a new formulation of Cyclosporine, in dry eye (beginning) CLIN [10 years]
2011 .01 Registration : positive advice from EMA on Cyclokat Phase III clinical trial for the treatment of Dry Eye Disease MKTG [10 years]
2010 .07 Listing on Euronext Paris : 22.0 M€ PBO [9 years]
2010 .04 Financing (no interest loan) : 9.4 M€, by OSEO, as the lead project company (with Stanipharm, Crossject, and CNRS) on retinopathy for Vitrena DEBT [9 years]
2009 .04 Clinical trial (phase II) for with Cyclokat, a new formulation of Cyclosporine, in dry eye (completion) CLIN [8 years]
2009 .02 Research : positive in vivo toxicity evaluation of BAK-free latanoprost formulation for glaucoma R&D [8 years]
2008 .12 Registration : provisionally negative opinion from EMEA for lead compound Vekacia (non convincing results : dossier is withdrawn) MKTG [8 years]
2008 .09 4th round-financing : 15.0 M€, by previous shareholders RFIND [8 years]
2008 .04 Launch of Cationorm on the French market, the first for the company MKTG [7 years]
2007 .03 Clinical trial (phase III) for Vekacia in Vernal Keratoconjonctivitis (VKC) (completed, positive) CLIN [6 years]
2006 .04 3rd round-financing : 26.0 M€, with AGF P.E., Bernard Chauvin Group, and previous shareholders RFINC [5 years]
2006 .01 Clinical trial (phase II) for Cyclosporin derivative (completed) CLIN [5 years]
2004 .12 2nd round-financing : 14.2 M€, with Edmond de Rothschild I.P., Siparex, and previous shareholders RFINB [4 years]
2004 .09 Nomination : Jérôme Martinez as CEO ORGN [4 years]
2000 .09 1st round-financing : 3.8 M€, with CDC Enterprise Innovation, Auriga Ventures, 123 Multinova, FJCE (CDC), Crédit Agricole P.E. RFINA [0 year]
2000 .08 Company founded by Prof. Simon Benita (Israel) and others ORGF [0 year]

Actualisation / Updating: 18-Nov-2012

 

* NOVEXEL *


 

2004 - IDF
Romainville
(near Paris)
www.novexel.com

 

Discovery, Drugs
Key words: Anti-infectives, Anti-fungals
Mission: to develop novel antibacterials designed to overcome the significant global problem of bacterial resistance
Clients: Prescribers
info@novexel.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Spin-off |
Managing Dir.-CEO: Buchanan (Iain) [born 1952, ex-Vertex, J&J, Biogen]
Sc.Dir.-CSO: Coleman (Kenneth) [Ph.D. microbiology, ex-AstraZeneca, SmithKline Beecham]
Fin.Dir.-CFO: Waldron (Gordon) [B.A. political science, ex-Syntem, Texas Instruments, Spie Batignolles]
BusDev: Mangasarian (Aram) [Ph.D. biology, MBA, ex-ExonHit Therapeutics]
Financers (Hist.): Sanofi-Aventis, Atlas Venture, Sofinnova, 3i, Abingworth, Novo

Turnover (M€) : 8.5 (2008)
Total funding (M€) : 90.0
Last funding (M€) : 50.0
Focus : Infections
Position : Clinical
Company confirm : neutral

 

History
DATEMILESTONETYPETIME
2010 .03 Company move from Romainville to USA (premises down, 40 staffs out) ORGL [5 years]
2009 .12 Acquisition by AstraZeneca (UK) for at least US$ 430 Millions ACQ- [5 years]
2008 .11 Clinical trial (phase II) for combined NXL104/ceftazidime in Hospital Patients with complicated Urinary Tract Infections (beginning) CLIN [4 years]
2008 .04 Licensing-out of NXL 104, a beta-lactamase inhibitor, to Forest (USA), with € 75 Millions upfront payment LICOUT [3 years]
2008 .01 Set-up of US subsidiary in Pennsylvania ORGC [3 years]
2007 .01 2nd round-financing : 50.0 M€, led by Edmond de Rothschild I.P., with Goldman Sachs, NeoMed, NIF SMBC, and previous shareholders RFINB [2 years]
2006 .12 Licensing-in of Aminocandin from Indevus Biotech (USA) LICIN [2 years]
2005 .10 Clinical trial (phase I) for NXL 103 (beginning) CLIN [1 year]
2004 .12 1st round-financing : 40.0 M€, led by Atlas Venture, with Sofinnova, 3i, Abingworth, Novo RFINA [0 year]
2004 .12 Company founded by Dominique Le Beller and others, as a spin-off from Sanofi-Aventis [ex-Aventis Pharma] ORGF [0 year]

Actualisation / Updating: 16-Mar-2010

 

* OPI *


 

1999 - Rhône-Alpes
Lyon
www.orphan-opi.com

 

Discovery, Drugs
Key words: Orphan diseases, Hematology, Cancer, Transplants, Kidrolase, Erwinase
Mission: to discover and develop new treatment for orphan diseases
Clients: Pharmaceutical industry
opi@orphan-opi.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Alberici (Gilles) [founder, Pharm.D., Ph.D. immunotoxicology, ex-Mérieux, IMTIX-Sangstat]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): founder, Biomérieux, Sofimac, CDC-PME, Innoveris, SPEF, Siparex

Turnover (M€) :
Total funding (M€) : 13.0
Last funding (M€) : 6.4
Focus : Multiple
Position : Preclin
Company confirm : n.a.

 

History
DATEMILESTONETYPETIME
2007 .03 Acquisition by Eusa Pharma (USA) ACQ- [8 years]
2004 .04 3rd round-financing : 6.4 M€, led by SPEF and Siparex, with previous shareholders RFINC [5 years]
2003 .05 Acquisition of Diaclone (France) ACQ+ [4 years]
2003 .00 2nd round-financing : 4.5 M€, by Sofimac, CDC-PME, Innoveris RFINB [3 years]
2001 .00 1st round-financing : 1.1 M€, by previous shareholders RFINA [1 year]
1999 .01 Company founded by Gilles Alberici [ex-Imtix, CEO], as 'Orphan Pharma International' ORGF [0 year]

Actualisation / Updating: 12-May-2008

 

* PHARMAXON *


 

2004 - Méditerranée
Marseille
www.pharmaxon.com

 

Discovery, Drugs
(also, Contract, Research)
Key words: Cell mobility, CNS
Mission: to develop new treatments or new research services to third parties, specialized in controlling cell mobility, as a technological breakthrough in neurology and neuro-oncology
Clients: Prescribers, Pharmaceutical industry, Research labs
contact@pharmaxon.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Spin-off |
Norreel (Jean-Chrétien) [co-founder, born 1970, Ph.D. neurosciences]
Sc.Dir.-CSO: Rougon (Geneviève) [co-founder, Ph.D., ex-CNRS, IBDM]
Oper.Dir.-COO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Inserm-Transfert Initiative, Esperante, Primavéris, CAAP Création, SHAM
Communication: no website news update since 2009 (in December 2012, the website is inactive), no legal information available since end 2009

Turnover (M€) : 0.062 (2009), 0.031 (2007), 0.13 (2006)
Total funding (M€) : 2.2
Last funding (M€) : 1.7
Focus : CNS
Position : Preclin
Company confirm : none

 

History
DATEMILESTONETYPETIME
2012 .01 Company simplified liquidation INFO [7 years]
2009 .11 1st round-financing : € 1.7 Million by SHAM (Société Hospitalière d'Assurances Mutuelles) and Primavéris RFINA [5 years]
2008 .11 Nomination : Glenn Stanley, as CEO, replacing Pascal Deschaseaux, moving as Gelarc Managing Director in Lyon (France) ORGN [4 years]
2007 .05 Licensing-in of PSA mimetic peptides from CNRS, 2 Universities and Schaffer-N (Denmark) LICIN [2 years]
2006 .10 Seed financing : 0.5 M€, by Inserm-Transfert Initiative, Esperante, Primavéris, Crédit Agricole AP Création SFIN [2 years]
2004 .09 Company founded by Pascal Deschaseaux [born 1960, M.D., MBA, ex-Pierre Fabre, Johnson & Johnson, Merck KGaA], Geneviève Rougon, Jean-Chrétien Norreel, as a spin-off from IBDM (Institut de Biologie et du Développement de Marseille-Luminy) ORGF [0 year]

Actualisation / Updating: 5-Dec-2012

 

* PRAXCELL *


 

2003 - Midi-Pyrénées
Ramonville Saint-Agne
(near Toulouse)
www.praxcell.com

 

Contract, Services
Key words: Medical devices, Cellular therapy, Stem cells, Cord blood, Kits, Hematopoietic, Endothelial
Mission: to supply human stem cells isolated from cord blood, human Umbilical Vein Endothelial Cells (HUVEC) and human Mesenchymal Stem Cells (MSC) prepared from the umbilical cord for the utilisation of stem cells in the medical, pharmaceutical, cosmetic and biotechnical researches
Clients: Research labs
commercial@praxcell.fr

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Eymeri (Michel) [co-founder, born 1954]
Sc.Dir.-CSO: Richard (Patrice) [co-founder, M.D.], Zeng (Lin) [co-founder, , born 1954, M.D.]
Oper.Dir.-COO: Prévots (Fabien) [born 1960]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Galia Gestion, Fonds d'Amorçage Midi-Pyrénées, privately owned

Turnover (M€) : 0.05 (2009), 0.03 (2008), 0.11 (2007)
Total funding (M€) : 1.2
Last funding (M€) : 0.5
Focus : Multiple
Position : Clinical
Company confirm : none

 

History
DATEMILESTONETYPETIME
2010 .10 Company liquidation INFO [6 years]
2007 .11 Round-financing : 1.5 M€, in preparation RFIN [4 years]
2006 .10 Seed financing : 0.5 M€, by Galia Gestion and Fonds d'Amorçage Midi Pyrénées SFIN [2 years]
2003 .11 Company founded by Dr Patrice Richard, Dr Lin Zeng, Michel Eymeri ORGF [0 year]

Actualisation / Updating: 28-Dec-2010

 

* PROTÉUS *


 

1998 - Méditerranée
Nîmes
www.proteus.fr

 

Design, Drugs
Key words: Proteins, Engineering, Manufacturing, Immunoline
Mission: to discover, engineer, optimize and manufacture new proteins and protein-based products and processes for third parties and own research
Clients: Pharmaceutical industry, Chemical industry (Degussa, Henkel, Aventis/Adisseo, Thales, Veolia Environment)
info@proteus.fr

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Ravot (Gilles) [born 1970, Ph.D. microbiology, Eng. ESIL, ex-Sanofi-Recherche]
Sc.Dir.-CSO: Ravot (Gilles)
Fin.Dir.-CFO: Vander Linden (Marc)
BusDev: Bloch (Jean-François) [also deputy CEO, co-founder, born 1961, Pharm.D., ex-Oris, CEA]
Financers (Hist.): PCAS (32%)
Notes : fully distinct from US-based biotech company Proteus Biomedical

Turnover (M€) : 2.07 (2008), 1.6 (2006)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Multiple
Position : Trade
Company confirm : neutral

 

History
DATEMILESTONETYPETIME
2010 .09 Acquisition by PCAS (100%), after minority share in 2007 ACQ- [12 years]
2007 .10 Round-financing : undisclosed M€, as a share capital increase reserved for industrial partner PCAS, from 6% to 32% RFIN [9 years]
2005 .07 Set-up of PSI, new division to trade protein services and production ORGC [7 years]
1999 .09 Seed financing : 0.2 M€, by Axa P.I., Natexis Ventech SFIN [1 year]
1998 .01 Company founded by Daniel Dupret (CEO, then President up to 2007) [co-founder, born 1956, Eng. Insa, ex-Transgene, Appligene], Jean-François Bloch, Jean-Marie Sonet [PCAS] and others ORGF [0 year]

Actualisation / Updating: 13-Dec-2010

 

$calcage="04/08/2004"; * SEPAL PHARMA *


 

2004 - IDF
Paris
www.no-website.net

 

Discovery, Drugs
Key words: Cancer, Jasmonate
Mission: to develop jasmonate derivatives as novel anticancer therapies (with its R&D laboratories in Nes Ziona, near Tel-Aviv, Israel)
Clients: Prescribers
info@sepalpharma.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Revah (Frédéric) [born 1968, Ph.D., Eng. Polytechnique, also Genethon Managing Dir. (2010- ), ex-Cerep, Rhône-Poulenc Rorer]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev: Herzberg (Max) [born 1940, Ph.D., ex-Orgenics (founder), D-Pharm (founder)] (also, Board Chairman)
Financers (Hist.): public (17%), founders (49%)
Note: beware, the website under www.sepalpharma.com has been hacked (December 2012)

Turnover (M€) : n.a.
Total funding (M€) : 3.8
Last funding (M€) : 3.8
Focus : Cancers
Position : Preclin
Company confirm : none

 

History
DATEMILESTONETYPETIME
2012 .06 Company simplified liquidation INFO [7 years]
2008 .04 Nomination : Dr Frédéric Revah, as CEO ORGN [3 years]
2007 .09 Management crisis : founder and CEO, Damien Salauze, on leave (for Institut Curie) ORG [3 years]
2005 .06 Listing on LSE (London) : 3.8 M€ PBO [0 year]
2004 .08 Company founded by Damien Salauze ([Pharm.D., MBA, ex-Auriga Partners, Rhône-Poulenc Rorer, Institut Pasteur], Christian Policard [ex-Sanofi], Max Herzberg and others, in Paris, with a subsidiary in Israel and a holding in London ORGF [0 year]

Actualisation / Updating: 7-Dec-2012

 

* SERIAL GENETICS *


 

2003 - IDF
Évry
(near Paris)
www.serialgenetics.com

 

Discovery, Diagnostics
(also, Contract, Research)
Key words: Kits, Biochips, Molecular biology, Mutation discovery, Endo-1 enzyme, HairLoop, SatArray, Charcot Disease
Mission: to develop and sell genetics analysis kits based on proprietary technology, HairLoop, and mutation discovery tools, based on the Endo-1 enzyme, to third parties
Clients: Research labs, Prescribers
contact@serialgenetics.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Valat (Christophe) [born 1964, co-founder, Ph.D. biosensors]
Sc.Dir.-CSO:
Fin.Dir.-CFO: Couget (Noëlle) [Ms. Finance]
BusDev: Nicolas (François) [co-founder, Ph.D.]
Financers (Hist.): privately held

Turnover (M€) : 0.04 (2008), 0.06 (2007), 0.03 (2006)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Multiple
Position : Trade
Company confirm : none

 

History
DATEMILESTONETYPETIME
2010 .03 Company struck off LEGAL [6 years]
2009 .07 Partnering development agreement with Gendiag (Spain) for Thrombo InCode R&D [5 years]
2009 .06 Financing (no interest loan) : 9.0 M€, by OSEO Innovation, for the NOSOBIO program for prevention, diagnostics and treatment of hospital-acquired infections (with Oncodesign, Palumed, Da Volterra, Institut Pasteur and Assistance Publique-Hôpitaux de Paris) DEBT [5 years]
2006 .08 Seed financing : 0.4 M€, by undisclosed investors SFIN [2 years]
2003 .10 Company founded by Christophe Valat and François Nicolas ORGF [0 year]

Actualisation / Updating: 9-May-2011

 

* SHIGAMEDIX *


 

2005 - IDF
Paris
www.shigamedix.com

 

Discovery, Immunology
Key words: Antigen vectorization, Vaccines, Cancer, Infectious diseases, STxB Platform
Mission: to develop new vaccines based on antigen vectorization STxB proprietary technology designed to specifically target the dendritic cells
Clients: Prescribers
info@shigamedix.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Spin-off |
Managing Dir.-CEO: Zacharie (Jean-Marie) [born 1941, HEC, Insead (MBA), ex-MSD]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned (registered capital 2006 = 0.04 M€)

Turnover (M€) : 0.036 (2007), 0.13 (2006)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Vaccines
Position : Preclin
Company confirm : none

 

History
DATEMILESTONETYPETIME
2009 .06 Company liquidation INFO [3 years]
2007 .11 Partnering research agreement with GSK Biologicals on vaccines R&D [2 years]
2006 .10 Nomination : Jean-Marie Zacharie, as President and CEO ORGN [1 year]
2005 .08 Company founded by Ludger Johannes [Ph.D.] from Curie Institute/CNRS and Eric Tartour [M.D./Ph.D.] ORGF [0 year]

Actualisation / Updating: 31-Oct-2008

 

* SYNT:EM *


 

1995 - Méditerranée
Nîmes
www.syntem.com

 

Discovery, Drugs
(also, Delivery, Drugs)
Key words: CNS, Brain barrier
Mission: to develop new drugs as well as to deliver compounds to the brain or other intracellular targets, based on proprietary Pep:trans and Acti:map technology platforms, in the field of CNS diseases
Clients: Prescribers
syntem@syntem.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Kaczorek (Michel)
Sc.Dir.-CSO:
Fin.Dir.-CFO: Waldron (Gordon)
BusDev:
Financers (Hist.): Apax Partners, Banexi Ventures, 3i, BankInvest, Lombart-Odier

Turnover (M€) :
Total funding (M€) : 32.0
Last funding (M€) : n.a.
Focus : CNS
Position : Clinical
Company confirm : n.a.

 

History
DATEMILESTONETYPETIME
2006 .01 Acquisition by CLL Pharma (France), a development stage drug delivery pharmaceutical company, in shares ACQ- [11 years]
2004 .11 Acquisition (failed) by Sonus (USA), for 30 MUS$ in shares ACQ- [9 years]
1995 .00 Company founded by Michel Kaczorek (CEO), Caroline Roussel ORGF [0 year]

Actualisation / Updating: 12-May-2008

 

* THERAPTOSIS *


 

2001 - IDF
Romainville
(near Paris)
www.theraptosis.com

 

Discovery, Drugs
Key words: Apoptosis control, Cancer, Neuro-degenerative diseases, CytoTrust, MitoTrust
Mission: to design and develop drugs acting on key apoptosis regulators to fight diseases associated with lack or excess of apoptosis including cancer and neurodegenerative diseases
Clients: Pharmaceutical industry (own development up to clinical trials)
info@theraptosis.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Spin-off |
Managing Dir.-CEO: Chesnoy (Olivier) [born 1958, M.D., ex-Fournier]
Sc.Dir.-CSO: Jacotot (Etienne) [Ph.D., ex-Theraptosis (CEO)]
Fin.Dir.-CFO: Boussard (Jean-François) [Ph.D.]
BusDev:
Financers (Hist.): Auriga Partners, EdRIP, SPEF, CDC, Blue Medical, Anvar

Turnover (M€) : 0.07 (2006)
Total funding (M€) : 16.7
Last funding (M€) : 8.4
Focus : Cancers
Position : Preclin
Company confirm : none

 

History
DATEMILESTONETYPETIME
2008 .12 Company liquidation (board of directors based decision) INFO [7 years]
2007 .09 Nomination : Olivier Chesnoy [M.D.] as CEO ORGN [6 years]
2007 .02 Company move to the Biocitech Park at Romainville (Paris North) ORGL [5 years]
2006 .12 2nd round-financing : 8.4 M€, led by Auriga Partners, with Blue Medical, Seventure, Edmond de Rothschild (EdRIP), CDC entreprises (FCJE) RFINB [5 years]
2006 .10 Registration : orphan drug designation by EMEA for a treatment of neonatal brain damage MKTG [5 years]
2002 .07 1st round-financing : 2.5 M€, by undisclosed investors RFINA [1 year]
2001 .03 Company founded by Léna Edelman and Etienne Jacotot, as a spin-off from Institut Pasteur, Paris ORGF [0 year]

Actualisation / Updating: 13-Nov-2009

 

* TRANSAT *


 

2002 - Rhône-Alpes
Saint-Priest
(near Lyon)
www.biotransat.com

 

Design, Drugs
(also Contract, Research)
Key words: Target delivery, Viral vectors, Functional genomics, Plasmid developments, Cellular models, Molecule libraries, RNA interference
Mission: to provide taylored cellular models and gene expression studies in functional genomics for third parties
Clients: Pharmaceutical industry, Biotech, Academic labs
transat@transatbiotechnology.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Chappuis (Sophie) [Ph.D., EM Lyon, ex-CNRS]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Evolem, Oseo, Région Rhône-Alpes, privately owned

Turnover (M€) : 0.5 (2006)
Total funding (M€) : 1.2
Last funding (M€) : 1.2
Focus : Genome
Position : Preclin
Company confirm : n.a.

 

History
DATEMILESTONETYPETIME
2008 .03 Company liquidation INFO [5 years]
2006 .01 Seed financing : 1.2 M€, by Evolem, Oseo, Région Rhône-Alpes, and Philippe Desmarescaux (born 1938), as business angel SFIN [3 years]
2002 .12 Company founded by Sophie Chappuis and Marc Billaud (CNRS) ORGF [0 year]

Actualisation / Updating: 12-May-2008

 

* UROGENE *


 

1998 - IDF
Paris
www.urogene.com

 

Discovery, Drugs
(also, Development, Drugs)
Key words: Urinary tract dysfunctions, Prostate, Bladder Cancer
Mission: to develop innovative drugs in urology
Clients: Pharmaceutical companies (own development up to phase III)
info@urogene.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Attali (Pierre) [born 1950, M.D., M.Sc., ex-Cerep, Molecular Engines Labs, Synthélabo]
Sc.Dir.-CSO: Bienaymé (Hugues) [born 1963, Ph.D. organic chemistry, ex-Chrysalon, Rhône-Poulenc Rorer]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Société Générale A.M., Capricorn Venture Partners, Nuage, FCJE (CDC), Genavent, OSEO-ANVAR

Turnover (M€) : n.a.
Total funding (M€) : 15.0
Last funding (M€) : 1.5
Focus : Cancers
Position : Clinical
Company confirm : none

 

History
DATEMILESTONETYPETIME
2011 .09 Company struck off LEGAL [13 years]
2008 .08 No website news update since November 2006 (net capital : - 3 M€ in December 2006, but legal capital increases in September 2007, August 2008, August 2009, February 2010) INFO [10 years]
2006 .01 Seed financing : 1.5 M€, by historical investors SFIN [7 years]
2005 .01 Divestiture of drug discovery platform (including Chrysalon) to Pierre Fabre ACQ- [6 years]
2004 .01 Licensing-in of Besipirdine exclusive rights from Aventis LICIN [5 years]
2003 .03 2nd round-financing : 12.0 M€, led by Société Générale Asset Management (SGAM) RFINB [5 years]
2002 .07 Acquisition of Chrysalon, a chemical company, spin-off from Aventis ACQ+ [4 years]
2000 .12 Nomination : Christian Grenier [born 1950, Sup de Co Paris, MBA, ex-Rhône Poulenc], as CEO ORGN [2 years]
2000 .09 1st round-financing : 2.0 M€, by Société Générale A.M., business angels RFINA [2 years]
1998 .04 Seed financing : 1.5 M€, by founders and public funding SFIN [0 year]
1998 .03 Company founded by Dr Philippe Berthon [CEO, Ph.D. cancerology], Dr Olivier Cussenot [CSO, Ph.D., M.D. surgery, Prof. urology], with Pierre Teillac [born 1960] and others ORGF [0 year]

Actualisation / Updating: 17-Dec-2011

 

* URRMA *


 

2001 - Méditerranée
Aubagne
(near Marseille)
www.urrma.eu

 

Discovery, Drugs
(also, Discovery, Diagnostics)
Key words: Antiretroviral, HIV, B-lymphocytes, R7V technology
Mission: to develop and bring to market innovative products in treatment and pronostic of HIV infected patients based on Professor Jean-Claude Chermann's knowledge of HIV disease
Clients: Prescribers
contact@urrma.eu

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Chermann (Jean-Claude) [born 1939, M.D., co-discoverer of AIDS virus, Professor, ex-Institut Pasteur, Inserm]
Sc.Dir.-CSO: Chermann (Jean-Claude) and Camille Haslin [Ph.D. sciences, ex-CNRS]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.):

Turnover (M€) : 1.75 (2008), 4.3 (2007)
Total funding (M€) : 15.0
Last funding (M€) : 9.0
Focus : Virus
Position : Preclin
Company confirm : none

 

History
DATEMILESTONETYPETIME
2010 .06 Company liquidation, with legal suite from Jean-Claude Chermann to minority shareholders INFO [9 years]
2008 .03 3rd round-financing : 9.0 M€, by undisclosed investors RFINC [6 years]
2005 .11 Round-financing : undisclosed M€, by private investors RFIN [4 years]
2001 .06 Company founded by Prof. Jean-Claude Chermann, Camille Haslin and Urrma Biopharma, based in Montreal, as a J.V. with a French subsidiary, which has since August 2004 become a French independent legal entity ORGF [0 year]

Actualisation / Updating: 5-Jul-2010

 

* VALIGEN *


 

1996 - IDF
Courbevoie (near Paris)
www.valigen.com

 

Discovery, Drugs
Key words: Genomics, Chimeraplasty
Mission: to research in therapeutic target identification and validation using the tools of functional genomics and gene expression analysis, for treatments of cardio-vascular and metabolic conditions, and some cancers
Clients: Pharmaceutical industry, Agro industry
webmaster@valigen.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Tharaud (Cécile) [Polytechnique, Ph.D., MBA, ex-Glaxo, SB]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.):

Turnover (M€) : 0.18 (2001)
Total funding (M€) : 30.0
Last funding (M€) : n.a.
Focus : Multiple
Position : Preclin
Company confirm : n.a.

 

History
DATEMILESTONETYPETIME
2002 .05 Company liquidation INFO [5 years]
2001 .05 Nomination : Cécile Tharaud, as CEO ORGN [4 years]
2000 .02 Acquisition of Kimeragen (USA), by merger ACQ+ [3 years]
1997 .02 Acquisition of Infogen (Germany) ACQ+ [0 year]
1996 .12 Company founded by Jean-Louis Pourny, from the merger of Valigène (France) and Kimeragen (USA) ORGF [0 year]

Actualisation / Updating: 12-May-2008

 

* VIGICELL *


 

1999 - IDF
Villejuif
(near Paris)
www.vigicell.eu

 

Contract, Services
Key words: Predictive toxicology, Genotoxicity, Toxichip, Angiogenesis
Mission: to provide third parties with services designing, performing and interpreting predictive toxicology tests, based on proprietary in-house developed tools
Clients: Research labs
vigicell@vigicell.fr

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Gilbert (Jean-Emmanuel) [born 1967, Ph.D.]
Sc.Dir.-CSO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): privately owned, with a minority share by SucSeed (a specialist biotech & IT seed fund) and Addes

Turnover (M€) : 0.23 (2009), 0.25 (2008), 0.2 (2006)
Total funding (M€) : n.a.
Last funding (M€) : 0.5
Focus : Studies
Position : Subcontractor
Company confirm : neutral

 

History
DATEMILESTONETYPETIME
2010 .09 Company liquidation INFO [11 years]
2008 .11 Seed financing : 0.5 M€, by business angels and private investors (undisclosed) SFIN [9 years]
2007 .06 Partnering research agreement with L'Oréal R&D [8 years]
2002 .05 Nomination : Jean-Emmanuel Gilbert [Ph.D.], as CEO ORGN [2 years]
1999 .06 Company founded by Yolène Thomas [Ph.D., CNRS], Jean-Paul Oudinet [Ph.D., CNRS], Isaac Béhar [Ph.D.] and others ORGF [0 year]

Actualisation / Updating: 9-May-2011

 

* ZETA BIOTECH *


 

2005 - Bretagne
Lannion
www.zetabiotech.com

 

Development, Diagnostics
Key words: Electrophoresis, Molecular gel, UltraPag
Mission: to develop and market a new generation of electrophoresis supports (UltraPag gel is the first deshydrated electrophoresis support worldwide)
Clients: Research labs, Pharmaceutical industry, Chemical industry
zetabiotech@zetabiotech.com

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Guyader (Antony) [co-founder, born 1976, M.Sc. biochemistry]
Sc.Dir.-CSO:
Fin.Dir.-CFO: Viola (Bruno) [co-founder, Sup de Co Brest, ex-Corvis, Alcatel, Pirelli/Cisco]
BusDev:
Financers (Hist.): privately-owned (founders, 60%), private investors, public

Turnover (M€) : 0.011 (2007)
Total funding (M€) : n.a.
Last funding (M€) : 1.5
Focus : Testing
Position : Trade
Company confirm : none

 

History
DATEMILESTONETYPETIME
2010 .04 Company liquidation INFO [4 years]
2008 .07 Production : set-up of full manufacturing line INDUS [2 years]
2007 .06 Listing on Euronext Paris : 1.5 M€ PBO [1 year]
2005 .10 Company founded by Antony Guyader and Bruno Viola ORGF [0 year]

Actualisation / Updating: 29-Jan-2011

 


Actualisation 15 Janvier 2017 / Updating 15 January 2017

Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende